Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Impax Laboratories
Impax Laboratories
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Manufacturing
Federal Equipment online auction of Impax packaging, processing and pharma assets
Do not miss Impax Laboratories’ pharmaceutical equipment auction 27–28 July
Manufacturing
Global online auction
Global Online Auction of quality surplus packaging, processing and pharmaceutical assets formerly of Impax Laboratories
Manufacturing
Impax Laboratories in capsule deal with Banner Pharmacaps
The two companies will collaborate on the supply of two softgel capsule products
Research & Development
GSK to sell Impax treatment for Parkinson’s Disease
Pays Impax US$11.5m upfront for exclusive licence
Subscribe now